Select Medical's 15min chart shows MACD Death Cross, Bearish Marubozu.
PorAinvest
lunes, 18 de agosto de 2025, 2:06 pm ET1 min de lectura
SEM--
The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a change in market sentiment from buyers to sellers. Similarly, the Bearish Marubozu candlestick pattern, characterized by a long body without any upper or lower wicks, suggests strong selling pressure with no reversal. These technical indicators, combined with the recent downward movement of the stock price, point to a bearish trend.
In addition to these technical indicators, Mizuho Financial Group has recently lowered its price target on Select Medical from $21.00 to $18.00, while maintaining an Outperform rating [1]. The price target reduction follows what Mizuho described as "disappointing" second-quarter 2025 earnings, with the company’s critical illness recovery hospital (LTCH) segment facing continued pressure from the Medicare high-cost outlier threshold and the 20% transmittal rule [1][2]. Despite these challenges, the company maintains profitability with $81.1 million in net income over the last twelve months [1].
Select Medical's inpatient rehabilitation (IRF) segment has been highlighted as a bright spot in the company’s operations, noted to be a highlight in the overall business [1][2]. The firm maintained its 2025-2027 estimates for Select Medical, expressing confidence that hospital operators should eventually adjust better to the higher Medicare outlier environment [1][2].
The market's current state of paralysis, awaiting the quarterly results of major companies such as ICICI Bank, HDFC Bank, and Reliance Industries, scheduled for release this weekend, may further exacerbate volatility [3]. These recent developments highlight the company’s performance and analyst perspectives. Investors are advised to exercise caution and diligent risk management in the face of these bearish indicators.
References:
[1] https://ng.investing.com/news/analyst-ratings/mizuho-lowers-select-medical-stock-price-target-to-18-on-ltch-segment-pressure-93CH-2054324
[2] https://za.investing.com/news/analyst-ratings/mizuho-lowers-select-medical-holdings-stock-price-target-on-ltch-segment-pressure-93CH-3831403
[3] https://www.ainvest.com/news/select-medical-15min-chart-shows-bearish-kdj-death-cross-marubozu-2508/
Select Medical's 15-minute chart has triggered a MACD Death Cross and a Bearish Marubozu at 08/18/2025 14:00, suggesting that the stock price has the potential to continue declining, with sellers dominating the market and a bearish momentum likely to persist.
Select Medical's (NYSE: SEM) 15-minute chart has exhibited significant bearish indicators, suggesting a potential continuation of its downward trajectory. On August 18, 2025, at 14:00, the chart triggered a MACD Death Cross and a Bearish Marubozu, signaling a shift in market sentiment towards sellers. These technical indicators suggest that the stock price may continue to decline, with a bearish momentum likely to persist.The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a change in market sentiment from buyers to sellers. Similarly, the Bearish Marubozu candlestick pattern, characterized by a long body without any upper or lower wicks, suggests strong selling pressure with no reversal. These technical indicators, combined with the recent downward movement of the stock price, point to a bearish trend.
In addition to these technical indicators, Mizuho Financial Group has recently lowered its price target on Select Medical from $21.00 to $18.00, while maintaining an Outperform rating [1]. The price target reduction follows what Mizuho described as "disappointing" second-quarter 2025 earnings, with the company’s critical illness recovery hospital (LTCH) segment facing continued pressure from the Medicare high-cost outlier threshold and the 20% transmittal rule [1][2]. Despite these challenges, the company maintains profitability with $81.1 million in net income over the last twelve months [1].
Select Medical's inpatient rehabilitation (IRF) segment has been highlighted as a bright spot in the company’s operations, noted to be a highlight in the overall business [1][2]. The firm maintained its 2025-2027 estimates for Select Medical, expressing confidence that hospital operators should eventually adjust better to the higher Medicare outlier environment [1][2].
The market's current state of paralysis, awaiting the quarterly results of major companies such as ICICI Bank, HDFC Bank, and Reliance Industries, scheduled for release this weekend, may further exacerbate volatility [3]. These recent developments highlight the company’s performance and analyst perspectives. Investors are advised to exercise caution and diligent risk management in the face of these bearish indicators.
References:
[1] https://ng.investing.com/news/analyst-ratings/mizuho-lowers-select-medical-stock-price-target-to-18-on-ltch-segment-pressure-93CH-2054324
[2] https://za.investing.com/news/analyst-ratings/mizuho-lowers-select-medical-holdings-stock-price-target-on-ltch-segment-pressure-93CH-3831403
[3] https://www.ainvest.com/news/select-medical-15min-chart-shows-bearish-kdj-death-cross-marubozu-2508/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios